Table 2. All calculated pooled HRs in meta-analysis.
| GROUP | AREA | OS | RFS/DFS | CSS | |||
| HR(95%CI) | I2 | HR(95%CI) | I2 | HR(95%CI) | I2 | ||
| All cancersa | Intratumoral | 1.66(1.37–2.01) | I2 = 70.5% | 1.68(1.36–2.07) | I2 = 55.8% | 3.36(2.08–5.42) | I2 = 0% |
| Peritumoral | 1.66(0.64–4.32) | I2 = 87.2% | 1.80(0.96–3.37) | I2 = 73.5% | ND | ND | |
| Stromal | 1.10(0.76–1.61) | I2 = 56.8% | 1.27(0.75–2.16) | I2 = 76.8% | ND | ND | |
| HCC and ICCa | Intratumoral | 1.80(1.33–2.43) | I2 = 57.7% | 1.58(1.33–1.88 ) | I2 = 36.9% | ND | ND |
| HNCa | Intratumoral | 1.69(1.10–2.60) | I2 = 0% | ND | ND | ND | ND |
| NSCLCa | Intratumoral | 1.16(1.00–1.35) | I2 = 0% | ND | ND | ND | ND |
| RCCa | Intratumoral | 2.69(1.89–3.83) | I2 = 0.0% | ND | ND | ND | ND |
| Gastrica | Intratumoral | 1.20(0.50–2.89) | I2 = 84.6% | ND | ND | ND | ND |
| CD66ba | Intratumoral | 1.80(1.47–2.22) | I2 = 67.7% | ND | ND | ND | ND |
| CD15a | Intratumoral | 1.44(0.90–2.30) | I2 = 45.9% | ND | ND | ND | ND |
| All cancers b | Intratumoral | 1.85(1.42–2.40) | I2 = 85.1% | 1.68(1.20–2.34) | I2 = 80.6% | 4.99(3.13–7.95) | I2 = 10.1% |
| Peritumoral | 1.28(0.62,2.66) | I2 = 87.8% | 1.78(0.97–3.28) | I2 = 81.8% | ND | ND | |
| Stromal | 1.10(0.76,1.61) | I2 = 56.8% | 1.27(0.75–2.16) | I2 = 76.8% | ND | ND | |
Abbreviations: HCC: hepatocellular carcinoma; ICC: intrahepatic cholangiocarcinoma; HNC: head and neck carcinoma, NSCLC: non-small-cell lung cancer; RCC: renal cell carcinoma; Gastric: gastric carcinoma; ND: not done. OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival; DFS: disease-free survival; a: maximally adjusted association HR ( When both unadjusted and adjusted HRs were extracted from the original papers, the adjusted HRs were included into analysis ); b: crude association HR ( When both unadjusted and adjusted HRs were extracted from the original papers, the unadjusted HRs were included into our analysis).